The system is based on magnetic materials rather than radioisotopes, and comprises the SentiMag® instrument and its magnetic tracer, Sienna+® to locate lymph nodes involved in the spread of cancer. Significant demand for the SentiMag® instruments demonstrates its early and growing acceptance into the market.
Endomagnetics’ CEO Dr Eric Mayes said, “From the outset of our great relationship with ITL, it was clear they were on our wavelength. As an aggressively growing start-up, we needed our partners to be equally dynamic and responsive. I didn’t necessarily expect this in an established manufacturing partner, but ITL demonstrated from the outset its natural ability to absorb the start-up enthusiasm.
“As soon as we engaged with ITL, the project really took off. Based on the relationship so far, I fully expect ITL will continue to play a fundamental role in Endomagnetics’ future products, manufacturing and order fulfilment. They are very much part of our team, and they really are committed to their customers.”
With qualified manufacturing facilities opened in China in 2008, which mirrors the Ashford UK facilities, ITL is well placed to support Endomagnetics’ manufacturing on a worldwide basis.